阿莫西林克拉维酸钾

Search documents
普洛药业:公司的奥司他韦、金刚乙胺等品种可用于流感病毒
Mei Ri Jing Ji Xin Wen· 2025-08-07 08:59
Core Viewpoint - The company has indicated that it offers medications that can treat viral infections such as influenza and bacterial infections, addressing concerns raised by investors regarding the current outbreak of diseases like chikungunya and influenza [2] Company Summary - The company, Prolo Pharmaceutical (000739.SZ), has stated that its products, including Oseltamivir and Amantadine, are effective against influenza viruses [2] - The company also provides a range of antibiotics such as Cefixime, Cefdinir, and Amoxicillin/Clavulanate Potassium for infection treatment [2]
全球克拉维酸钾原料药总体规模及主要厂商占有率和排名
QYResearch· 2025-06-27 09:56
Core Viewpoint - The global market for potassium clavulanate API is projected to reach $700 million by 2031, with a compound annual growth rate (CAGR) of 5.2% in the coming years [1]. Market Overview - Potassium clavulanate is a β-lactamase inhibitor commonly used in combination with penicillin antibiotics, enhancing their antibacterial effectiveness [1]. - The market is primarily driven by the increasing demand for combination formulations due to rising antibiotic resistance [9]. Market Size and Growth - According to QYResearch, the global potassium clavulanate API market is expected to grow significantly, with the leading product being amoxicillin-clavulanate [6][8]. - The oral formulation segment accounts for approximately 74% of the market share, indicating a strong preference for this application [8]. Key Players - Major manufacturers in the potassium clavulanate API market include China National Pharmaceutical Group, GSK, Shandong New Era Pharmaceutical, and others, with the top three companies holding about 63% of the market share in 2024 [6][13]. Market Trends - The market is experiencing a shift towards green synthesis methods, such as enzyme-based processes, which are expected to replace traditional chemical methods, reducing energy consumption and pollution [8]. - The demand for potassium clavulanate is also bolstered by improvements in clinical recognition of its value in treating infectious diseases [9]. Challenges - The market faces challenges such as increasing environmental regulations that raise compliance costs for manufacturers [10]. - The emergence of new β-lactamase inhibitors poses a potential threat to the market share of potassium clavulanate [10]. - International trade barriers and varying regulatory standards across countries complicate market access and increase costs [10].